GSK in £1.2bn deal for sleeping pill rights
Tuesday 15 July 2008
The UK's biggest pharmaceutical group, GlaxoSmithKline, is to pay up to £1.2bn for the rights to develop and sell almorexant, an anti-insomnia treatment in its final stage of testing.
GSK will initially spend £66m to help the drug's Swiss maker, Actelion, push the sleeping pill through its phase three trials in Europe. Assuming almorexant passes the licencing requirements, Glaxo's will be liable to pay additional sums relating to sales and other applications for the treatment.
A spokesperson for the group said yesterday the deal was unlikely to result in the whole £1.2bn being paid and declined to comment on what other trials were likely for almorexant.
According to analysts at Dresdner Kleinwort, almorexant is expected to be ready for market by 2011. With 80 million sufferers in the United States alone, experts at JP Morgan Cazenove argue that the US market for insomnia treatments is worth up to $1.2bn.
GSK and Actelion have agreed to continue to pool research into insomnia treatments, although at present this does not extend beyond almorexant.
Analysts covering GSK had one eye on the group's interim results, due next week. It will be one of the first chances the group's chief executive, Andrew Witty, has had to talk directly to shareholders who have seen the stock fall steadily over the past 12 months.
Jeremy Batstone-Carr, an analyst at Charles Stanley, reckons that Mr Witty will take the opportunity to outline his strategy, two months into the job.
- 1 Autistic adults could take pure MDMA to 'reduce social anxiety'
- 2 Stolen Instagram photo sells for $90,000
- 3 Before you complain about your GP, this is what you need to know about actually doing the job
- 4 Charlie Charlie Challenge explained: not a Mexican demon being summoned — it's gravity
- 5 Paracetamol Challenge: Mother of girl killed by overdose pleads with teenagers not to take part
Iran launches anti-Isis cartoon competition 'to expose true nature of Islamic State'
'Don't blame all men for rape' campaign backfires spectacularly
Fifa corruption arrests: How Chuck Blazer rinsed money from the beautiful game
Fifa corruption live: Uefa to consider pulling teams from Fifa tournaments if Blatter stays
Ukip MP Douglas Carswell says he felt his safety was 'seriously at risk' after he was surrounded by anti-austerity protesters
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
The day that Britain resigned as a global power
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Australian man punched in the face for defending Muslim women from abuse on train
A nation of inequality: How the UK is failing to feed its most vulnerable people
David Starkey 'tells Amal Clooney to shut up and stop over-promoting human rights'
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...